Clinical trials: HiV1- Positive
HIV Infections
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)
The aim of the study is to establish if human immunodeficiency virus type 1 (HIV-1) infected adult participants with current virologic suppression on a >=3-drug tenofovir alafenamide (TAF) based regimen (TBR) remain suppressed…
- Trial name
- NCT03446573
- Testing
- DTG + 3TC, TAF based regimen (TBR)
- Where
- 133 sites in United States, Australia and 8 more
- Volunteers
- 743 people
- Sponsor
- ViiV Healthcare
HIV Infection
A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701
This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B*5701 can reduce the incidence of hypersensitivity reactions to abacavir).
- Trial name
- NCT00435838
- Testing
- No Intervention -- Observational study
- Where
- 25 sites in Austria, Belgium and 5 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
HIV, HIV Infections
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen.
- Conditions
- HIV, HIV Infections, Acquired Immunodeficiency Syndrome
- Trial name
- NCT01967940
- Testing
- TAF, E/C/F/TAF, Current failing ARV regimen
- Where
- 15 sites in United States, Dominican Republic and 3 more
- Volunteers
- 55 people
- Sponsor
- Gilead Sciences
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195312
- Testing
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 91 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV-1
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
The purpose of this Observational Study is long term follow-up of the Human Immunodeficiency Virus -1 (HIV-1) infected patients who have received a gene therapy product (anti-HIV-1 Ribozyme [OZ1]) as part of an earlier phase 2…
- Trial name
- NCT01177059
- Testing
- OZ1 transduced cells
- Where
- 6 sites in United States, Australia
- Volunteers
- 68 people
- Sponsor
- Janssen-Cilag Pty Ltd
HIV-1 Infection
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are…
- Trial name
- NCT02121795
- Testing
- FTC/TDF, F/TAF, Allowed third antiretroviral agent
- Where
- 78 sites in United States, Belgium and 5 more
- Volunteers
- 668 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC…
- Trial name
- NCT02469246
- Testing
- F/TAF, ABC/3TC, 3rd ARV agent
- Where
- 80 sites in United States, Belgium and 10 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
HIV Infection
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard…
- Trial name
- KALEAD (NCT00234910)
- Testing
- Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Abbott
HIV Infections
A Study of T-20 in HIV-Positive Adults
The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.
- Trial name
- NCT00002228
- Testing
- Enfuvirtide
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Trimeris
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Lipodystrophy
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus…
- Trial name
- NCT00005764
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
HIV Infections
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
- Trial name
- NCT00005001
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agouron Pharmaceuticals
HIV-1 Infection
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
- Trial name
- NCT01097070
- Testing
- Bevirimat
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Myrexis Inc.
HIV Infections
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
- Trial name
- NCT00002235
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
The purpose of this Phase I, open-label, single sequence drug-drug interaction trial in human immunodeficiency virus-type 1 infected patients is to investigate the potential interaction between steady-state nevirapine (NVP) 200…
- Trial name
- NCT00910806
- Testing
- TMC207; nevirapine
- Where
- South Africa
- Volunteers
- 16 people
- Sponsor
- Tibotec BVBA
HIV Infections
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients.
- Trial name
- NCT00967187
- Testing
- bevirimat dimeglumine
- Where
- 4 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Myrexis Inc.
HIV Infections
A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)
A study comparing Indinavir plus Ritonavir plus 2 NRTIs vs. Nelfinavir 1250 plus two nucleoside reverse transcriptase inhibitors (NRTIs) in the treatment of HIV positive patients who have not responded to or are intolerant to a…
- Trial name
- NCT00541463
- Testing
- MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks, Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
HIV Vaccine Study in HIV Positive Patients
The purpose of the study is to see whether a single vaccination (injection) with the investigational HIV vaccine is safe and effective in patients who are HIV positive but have not yet begun anti-retroviral therapy.
- Trial name
- NCT01071031
- Testing
- HIV-v (Low Dose), HIV-v (High Dose), HIV-v (Control)
- Where
- 5 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- PepTcell Limited
HIV, HIV Infections
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and…
- Trial name
- NCT01818596
- Testing
- E/C/F/TAF
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 252 people
- Sponsor
- Gilead Sciences
HIV Infections
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.
- Trial name
- NCT00736502
- Where
- 17 sites in Austria, Poland
- Volunteers
- 280 people
- Sponsor
- Boehringer Ingelheim